We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The U.S. Supreme Court largely upheld the constitutionality of the healthcare reform law known as the Affordable Care Act, thus allowing the Food and Drug Administration (FDA) to move forward with the implementation of provisions creating an approval pathway for biosimilars, generic drugs that are the equivalent of brand-name biologics
Bipartisan legislation has been introduced in the U.S. House of Representatives and the U.S. Senate (H.R. 2632, S. 1410) to encourage life sciences investment by increasing the existing research and development (R&D) tax credit
The U.S. Qualifying Therapeutic Discovery Project Program has recently identified the biotech companies that will receive part of $1 billion in tax credits or grants under the Affordable Care Act to stimulate research and development
